The trajectory of companies tied to Sildenafil's history presents a complex investment picture . While the initial boom generated substantial returns , generic alternatives have significantly eroded market share . Investing in connected pharmaceutical companies now requires a discerning assessment of patent protection , evolving healthcare trends ,